Cellular transformation by human papillomaviruses: Lessons learned by comparing high- and low-risk viruses

Virology

Volumn 424, Issue 2, 2012, Pages 77-98

  Klingelhutz, Aloysius J ^a   Roman, Ann ^b  

^a UNIVERSITY OF IOWA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

HPV and differentiation; HPV cellular transformation; HPV E5; HPV E6; HPV E7; HPV life cycle; HPV pathogenesis; Human papillomaviruses; P53; Rb

Indexed keywords

CYCLIN DEPENDENT KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; PDZ PROTEIN; PROTEIN BAK; PROTEIN E6; PROTEIN E7; PROTEIN P53; TELOMERASE; VIRUS DNA;

ACETYLATION; AUTOPHAGY; BINDING AFFINITY; BINDING SITE; CANCER SUSCEPTIBILITY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL TRANSFORMATION; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; KERATINOCYTE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RISK ASSESSMENT; RNA TRANSLATION; SEQUENCE ALIGNMENT; SHORT SURVEY; TRANSGENE; UPREGULATION; UTERINE CERVIX CARCINOMA; VIRION; VIRUS GENOME; VIRUS REPLICATION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANIMALS; CELL TRANSFORMATION, VIRAL; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84857033535     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.12.018     Document Type: Short Survey

References (366)

1. Accardi R., Dong W., Smet A., Cui R., Hautefeuille A., Gabet A.S., Sylla B.S., Gissmann L., Hainaut P., Tommasino M. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 2006, 7:334-340.
2. Ai W., Toussaint E., Roman A. CCAAT displacement protein binds to and negatively regulates human papillomavirus type 6 E6, E7, and E1 promoters. J. Virol. 1999, 73:4220-4229.
3. Ai W., Narahari J., Roman A. Yin yang 1 negatively regulates the differentiation-specific E1 promoter of human papillomavirus type 6. J. Virol. 2000, 74:5198-5205.
4. Akgul B., Garcia-Escudero R., Ghali L., Pfister H.J., Fuchs P.G., Navsaria H., Storey A. The E7 protein of cutaneous human papillomavirus type 8 causes invasion of human keratinocytes into the dermis in organotypic cultures of skin. Cancer Res. 2005, 65:2216-2223.
5. Alfandari J., Shnitman Magal S., Jackman A., Schlegel R., Gonen P., Sherman L. HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. Virology 1999, 257:383-396.
6. Allison S.J., Jiang M., Milner J. Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells. Aging (Albany NY) 2009, 1:316-327.
7. An J., Mo D., Liu H., Veena M.S., Srivatsan E.S., Massoumi R., Rettig M.B. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell 2008, 14:394-407.
8. Antinore M.J., Birrer M.J., Patel D., Nader L., McCance D.J. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 1996, 15:1950-1960.
9. Armstrong D.J., Roman A. Human papillomavirus type 6 E7 protein is a substrate in vitro of protein kinase C. Biochem. J. 1995, 312(Pt 3):667-670.
10. Armstrong D.J., Roman A. The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent. Virology 1997, 239:238-246.
11. Arroyo M., Bagchi S., Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol. Cell. Biol. 1993, 13:6537-6546.
12. Au Yeung C.L., Tsang T.Y., Yau P.L., Kwok T.T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011, 30:2401-2410.
13. Avvakumov N., Torchia J., Mymryk J.S. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 2003, 22:3833-3841.
14. Baldwin A., Huh K.W., Munger K. Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J. Virol. 2006, 80:6669-6677.
15. Band V., De Caprio J.A., Delmolino L., Kulesa V., Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J. Virol. 1991, 65:6671-6676.
16. Band V., Dalal S., Delmolino L., Androphy E.J. Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J. 1993, 12:1847-1852.
17. Banerjee N.S., Wang H.K., Broker T.R., Chow L.T. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. J. Biol. Chem. 2011, 286:15473-15482.
18. Banks L., Barnett S.C., Crook T. HPV-16 E7 functions at the G1 to S phase transition in the cell cycle. Oncogene 1990, 5:833-837.
19. Banks L., Edmonds C., Vousden K.H. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 1990, 5:1383-1389.
20. Barbosa M.S., Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989, 4:1529-1532.
21. Barbosa M.S., Lowy D.R., Schiller J.T. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J. Virol. 1989, 63:1404-1407.
22. Barbosa M.S., Edmonds C., Fisher C., Schiller J.T., Lowy D.R., Vousden K.H. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 1990, 9:153-160.
23. Barbosa M.S., Vass W.C., Lowy D.R., Schiller J.T. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J. Virol. 1991, 65:292-298.
24. Barrow-Laing L., Chen W., Roman A. Low- and high-risk human papillomavirus E7 proteins regulate p130 differently. Virology 2010, 400:233-239.
25. Bedard K.M., Underbrink M.P., Howie H.L., Galloway D.A. The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. J. Virol. 2008, 82:3894-3902.
26. Bedell M.A., Jones K.H., Laimins L.A. The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells. J. Virol. 1987, 61:3635-3640.
27. Bedell M.A., Jones K.H., Grossman S.R., Laimins L.A. Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J. Virol. 1989, 63:1247-1255.
28. Beglin M., Melar-New M., Laimins L. Human papillomaviruses and the interferon response. J. Interferon Cytokine Res. 2009, 29:629-635.
29. Berezutskaya E., Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J. Biol. Chem. 1997, 272:30135-30140.
30. Berezutskaya E., Yu B., Morozov A., Raychaudhuri P., Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ. 1997, 8:1277-1286.
31. Bernat A., Avvakumov N., Mymryk J.S., Banks L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 2003, 22:7871-7881.
32. Bischof O., Nacerddine K., Dejean A. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol. Cell. Biol. 2005, 25:1013-1024.
33. Bodily J.M., Mehta K.P., Cruz L., Meyers C., Laimins L.A. The E7 open reading frame acts in cis and in trans to mediate differentiation-dependent activities in the human papillomavirus type 16 life cycle. J. Virol. 2011, 85:8852-8862.
34. Bodily J.M., Mehta K.P., Laimins L.A. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res. 2011, 71:1187-1195.
35. Bohm S., Wilczynski S.P., Pfister H., Iftner T. The predominant mRNA class in HPV16-infected genital neoplasias does not encode the E6 or the E7 protein. Int. J. Cancer 1993, 55:791-798.
36. Bollmann F.M. The many faces of telomerase: emerging extratelomeric effects. Bioessays 2008, 30:728-732.
37. Bouvard V., Matlashewski G., Gu Z.M., Storey A., Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 1994, 203:73-80.
38. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56:4620-4624.
39. Brehm A., Nielsen S.J., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999, 18:2449-2458.
40. Brimer N., Lyons C., Vande Pol S.B. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein. Virology 2007, 358:303-310.
41. Brooks L.A., Sullivan A., O'Nions J., Bell A., Dunne B., Tidy J.A., Evans D.J., Osin P., Vousden K.H., Gusterson B., Farrell P.J., Storey A., Gasco M., Sakai T., Crook T. E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br. J. Cancer 2002, 86:263-268.
42. Burgers W.A., Blanchon L., Pradhan S., de Launoit Y., Kouzarides T., Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007, 26:1650-1655.
43. Caldeira S., Zehbe I., Accardi R., Malanchi I., Dong W., Giarre M., de Villiers E.M., Filotico R., Boukamp P., Tommasino M. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 2003, 77:2195-2206.
44. Carlotti F., Crawford L. Trans-activation of the adenovirus E2 promoter by human papillomavirus type 16 E7 is mediated by retinoblastoma-dependent and -independent pathways. J. Gen. Virol. 1993, 74(Pt 11):2479-2486.
45. Cerni C., Patocka K., Meneguzzi G. Immortalization of primary rat embryo cells by human papillomavirus type 11 DNA is enhanced upon cotransfer of ras. Virology 1990, 177:427-436.
46. Chakrabarti O., Veeraraghavalu K., Tergaonkar V., Liu Y., Androphy E.J., Stanley M.A., Krishna S. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J. Virol. 2004, 78:5934-5945.
47. Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., Nevins J.R. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4549-4553.
48. Chen S.L., Mounts P. Transforming activity of E5a protein of human papillomavirus type 6 in NIH 3T3 and C127 cells. J. Virol. 1990, 64:3226-3233.
49. Chen J.J., Reid C.E., Band V., Androphy E.J. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995, 269:529-531.
50. Chen J.J., Hong Y., Rustamzadeh E., Baleja J.D., Androphy E.J. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J. Biol. Chem. 1998, 273:13537-13544.
51. Cheng S., Schmidt-Grimminger D.C., Murant T., Broker T.R., Chow L.T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 1995, 9:2335-2349.
52. Chesters P.M., McCance D.J. Human papillomavirus types 6 and 16 in cooperation with Ha-ras transform secondary rat embryo fibroblasts. J. Gen. Virol. 1989, 70(Pt 2):353-365.
53. Chesters P.M., Vousden K.H., Edmonds C., McCance D.J. Analysis of human papillomavirus type 16 open reading frame E7 immortalizing function in rat embryo fibroblast cells. J. Gen. Virol. 1990, 71(Pt 2):449-453.
54. Chien W.M., Parker J.N., Schmidt-Grimminger D.C., Broker T.R., Chow L.T. Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry. Cell Growth Differ. 2000, 11:425-435.
55. Choi J., Southworth L.K., Sarin K.Y., Venteicher A.S., Ma W., Chang W., Cheung P., Jun S., Artandi M.K., Shah N., Kim S.K., Artandi S.E. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 2008, 4:e10.
56. Ciccolini F., Di Pasquale G., Carlotti F., Crawford L., Tommasino M. Functional studies of E7 proteins from different HPV types. Oncogene 1994, 9:2633-2638.
57. Collins A.S., Nakahara T., Do A., Lambert P.F. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J. Virol. 2005, 79:14769-14780.
58. Conrad M., Bubb V.J., Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J. Virol. 1993, 67:6170-6178.
59. Cordano P., Gillan V., Bratlie S., Bouvard V., Banks L., Tommasino M., Campo M.S. The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology 2008, 377:408-418.
60. Crook T., Tidy J.A., Vousden K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991, 67:547-556.
61. Dalal S., Gao Q., Androphy E.J., Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol. 1996, 70:683-688.
62. Davies R., Hicks R., Crook T., Morris J., Vousden K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol. 1993, 67:2521-2528.
63. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
64. DeFilippis R.A., Goodwin E.C., Wu L., DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J. Virol. 2003, 77:1551-1563.
65. Demers G.W., Foster S.A., Halbert C.L., Galloway D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4382-4386.
66. Demers G.W., Halbert C.L., Galloway D.A. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 1994, 198:169-174.
67. Demers G.W., Espling E., Harry J.B., Etscheid B.G., Galloway D.A. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J. Virol. 1996, 70:6862-6869.
68. DiPaolo J.A., Woodworth C.D., Popescu N.C., Notario V., Doniger J. Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras. Oncogene 1989, 4:395-399.
69. Dong W., Kloz U., Accardi R., Caldeira S., Tong W.M., Wang Z.Q., Jansen L., Durst M., Sylla B.S., Gissmann L., Tommasino M. Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J. Virol. 2005, 79:14899-14908.
70. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond) 2006, 110:525-541.
71. Doorbar J., Parton A., Hartley K., Banks L., Crook T., Stanley M., Crawford L. Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology 1990, 178:254-262.
72. Dreher A., Rossing M., Kaczkowski B., Andersen D.K., Larsen T.J., Christophersen M.K., Nielsen F.C., Norrild B. Differential expression of cellular microRNAs in HPV 11, -16, and -45 transfected cells. Biochem. Biophys. Res. Commun. 2011, 412:20-25.
73. Duensing S., Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002, 62:7075-7082.
74. Duensing S., Munger K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J. Virol. 2003, 77:12331-12335.
75. Duensing S., Lee L.Y., Duensing A., Basile J., Piboonniyom S., Gonzalez S., Crum C.P., Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10002-10007.
76. Duffy C.L., Phillips S.L., Klingelhutz A.J. Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6. Virology 2003, 314:196-205.
77. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
78. Dyson N., Guida P., Munger K., Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 1992, 66:6893-6902.
79. Edmonds C., Vousden K.H. A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 1989, 63:2650-2656.
80. Eichten A., Westfall M., Pietenpol J.A., Munger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology 2002, 295:74-85.
81. Elbel M., Carl S., Spaderna S., Iftner T. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 1997, 239:132-149.
82. Fehrmann F., Klumpp D.J., Laimins L.A. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J. Virol. 2003, 77:2819-2831.
83. Feltkamp M.C., de Koning M.N., Bavinck J.N., Ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J. Clin. Virol. 2008, 43:353-360.
84. Filippova M., Song H., Connolly J.L., Dermody T.S., Duerksen-Hughes P.J. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 2002, 277:21730-21739.
85. Filippova M., Parkhurst L., Duerksen-Hughes P.J. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 2004, 279:25729-25744.
86. Filippova M., Johnson M.M., Bautista M., Filippov V., Fodor N., Tungteakkhun S.S., Williams K., Duerksen-Hughes P.J. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 2007, 81:4116-4129.
87. Filippova M., Filippov V.A., Kagoda M., Garnett T., Fodor N., Duerksen-Hughes P.J. Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J. Virol. 2009, 83:210-227.
88. Fillippovich I., Sorokina N., Gatei M., Haupt Y., Hobson K., Moallem E., Spring K., Mould M., McGuckin M.A., Lavin M.F., Khanna K.K. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 2001, 20:514-522.
89. Firzlaff J.M., Galloway D.A., Eisenman R.N., Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol. 1989, 1:44-53.
90. Firzlaff J.M., Luscher B., Eisenman R.N. Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:5187-5191.
91. Flores E.R., Allen-Hoffmann B.L., Lee D., Lambert P.F. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 2000, 74:6622-6631.
92. Forslund O., Iftner T., Andersson K., Lindelof B., Hradil E., Nordin P., Stenquist B., Kirnbauer R., Dillner J., de Villiers E.M. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. J. Infect. Dis. 2007, 196:876-883.
93. Foster S.A., Demers G.W., Etscheid B.G., Galloway D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 1994, 68:5698-5705.
94. Foster S.A., Wong D.J., Barrett M.T., Galloway D.A. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 1998, 18:1793-1801.
95. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997, 11:2090-2100.
96. Gage J.R., Meyers C., Wettstein F.O. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 1990, 64:723-730.
97. Gao Q., Srinivasan S., Boyer S.N., Wazer D.E., Band V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol. Cell. Biol. 1999, 19:733-744.
98. Gardiol D., Kuhne C., Glaunsinger B., Lee S.S., Javier R., Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 1999, 18:5487-5496.
99. Genovese N.J., Banerjee N.S., Broker T.R., Chow L.T. Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J. Virol. 2008, 82:4862-4873.
100. Genovese N.J., Broker T.R., Chow L.T. Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein. J. Virol. 2011, 85:5546-5554.
101. Genther Williams S.M., Disbrow G.L., Schlegel R., Lee D., Threadgill D.W., Lambert P.F. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 2005, 65:6534-6542.
102. Genther S.M., Sterling S., Duensing S., Munger K., Sattler C., Lambert P.F. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 2003, 77:2832-2842.
103. Gewin L., Galloway D.A. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J. Virol. 2001, 75:7198-7201.
104. Gewin L., Myers H., Kiyono T., Galloway D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004, 18:2269-2282.
105. Ghittoni R., Accardi R., Hasan U., Gheit T., Sylla B., Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40:1-13.
106. Giarre M., Caldeira S., Malanchi I., Ciccolini F., Leao M.J., Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J. Virol. 2001, 75:4705-4712.
107. Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 1981, 23:175-182.
108. Gonzalez S.L., Stremlau M., He X., Basile J.R., Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 2001, 75:7583-7591.
109. Greco D., Kivi N., Qian K., Leivonen S.K., Auvinen P., Auvinen E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 2011, 6:e21646.
110. Grossman S.R., Mora R., Laimins L.A. Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J. Virol. 1989, 63:366-374.
111. Guccione E., Massimi P., Bernat A., Banks L. Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. Virology 2002, 293:20-25.
112. Guccione E., Lethbridge K.J., Killick N., Leppard K.N., Banks L. HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures. Oncogene 2004, 23:4662-4672.
113. Halbert C.L., Demers G.W., Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 1991, 65:473-478.
114. Halbert C.L., Demers G.W., Galloway D.A. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 1992, 66:2125-2134.
115. Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 1995, 55:4420-4424.
116. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989, 8:3905-3910.
117. He W., Staples D., Smith C., Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J. Virol. 2003, 77:10566-10574.
118. Hebner C., Beglin M., Laimins L.A. Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. J. Virol. 2007, 81:12740-12747.
119. Heck D.V., Yee C.L., Howley P.M., Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4442-4446.
120. Heilman S.A., Nordberg J.J., Liu Y., Sluder G., Chen J.J. Abrogation of the postmitotic checkpoint contributes to polyploidization in human papillomavirus E7-expressing cells. J. Virol. 2009, 83:2756-2764.
121. Helt A.M., Galloway D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 2001, 75:6737-6747.
122. Helt A.M., Funk J.O., Galloway D.A. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J. Virol. 2002, 76:10559-10568.
123. Herber R., Liem A., Pitot H., Lambert P.F. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol. 1996, 70:1873-1881.
124. Hickman E.S., Picksley S.M., Vousden K.H. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 1994, 9:2177-2181.
125. Hiraiwa A., Kiyono T., Segawa K., Utsumi K.R., Ohashi M., Ishibashi M. Comparative study on E6 and E7 genes of some cutaneous and genital papillomaviruses of human origin for their ability to transform 3Y1 cells. Virology 1993, 192:102-111.
126. Holland D., Hoppe-Seyler K., Schuller B., Lohrey C., Maroldt J., Durst M., Hoppe-Seyler F. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res. 2008, 68:9964-9972.
127. Hong S., Mehta K.P., Laimins L.A. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 2011, 85:9486-9494.
128. Hoover A.C., Strand G.L., Nowicki P.N., Anderson M.E., Vermeer P.D., Klingelhutz A.J., Bossler A.D., Pottala J.V., Hendriks W.J., Lee J.H. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009, 28:3960-3970.
129. Howie H.L., Katzenellenbogen R.A., Galloway D.A. Papillomavirus E6 proteins. Virology 2009, 384:324-334.
130. Howie H.L., Koop J.I., Weese J., Robinson K., Wipf G., Kim L., Galloway D.A. Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog. 2011, 7:e1002211.
131. Howley P.M., Lowy D.R. Papillomaviruses. Fields Virology 2007, 2299-2354. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
132. Hu T., Ferril S., Snider A., Barbosa M. In-vivo analysis of hpv e7 protein association with prb, p107 and p130. Int. J. Oncol. 1995, 6:167-174.
133. Huang S.M., McCance D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 2002, 76:8710-8721.
134. Huang P.S., Patrick D.R., Edwards G., Goodhart P.J., Huber H.E., Miles L., Garsky V.M., Oliff A., Heimbrook D.C. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol. Cell. Biol. 1993, 13:953-960.
135. Hudson J.B., Bedell M.A., McCance D.J., Laiminis L.A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J. Virol. 1990, 64:519-526.
136. Huh K.W., DeMasi J., Ogawa H., Nakatani Y., Howley P.M., Munger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11492-11497.
137. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 2007, 81:9737-9747.
138. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991, 10:4129-4135.
139. Huibregtse J.M., Scheffner M., Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol. 1993, 13:4918-4927.
140. Hurlin P.J., Kaur P., Smith P.P., Perez-Reyes N., Blanton R.A., McDougall J.K. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:570-574.
141. Hussain I., Fathallah I., Accardi R., Yue J., Saidj D., Shukla R., Hasan U., Gheit T., Niu Y., Tommasino M., Sylla B.S. NF-kappaB protects human papillomavirus type 38 E6/E7-immortalized human keratinocytes against tumor necrosis factor alpha and UV-mediated apoptosis. J. Virol. 2011, 85:9013-9022.
142. Hwang E.S., Nottoli T., Dimaio D. The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995, 211:227-233.
143. Hwang S.G., Lee D., Kim J., Seo T., Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 2002, 277:2923-2930.
144. Jackson S., Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000, 19:592-598.
145. James M.A., Lee J.H., Klingelhutz A.J. HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300. Int. J. Cancer 2006, 119:1878-1885.
146. James M.A., Lee J.H., Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol. 2006, 80:5301-5307.
147. Javier R.T. Cell polarity proteins: common targets for tumorigenic human viruses. Oncogene 2008, 27:7031-7046.
148. Jeon S., Allen-Hoffmann B.L., Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 1995, 69:2989-2997.
149. Jeong K.W., Kim H.Z., Kim S., Kim Y.S., Choe J. Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation. Oncogene 2007, 26:487-499.
150. Jewers R.J., Hildebrandt P., Ludlow J.W., Kell B., McCance D.J. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol. 1992, 66:1329-1335.
151. Jha S., Vande Pol S., Banerjee N.S., Dutta A.B., Chow L.T., Dutta A. Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway. Mol. Cell 2010, 38:700-711.
152. Jing M., Bohl J., Brimer N., Kinter M., Vande Pol S.B. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J. Virol. 2007, 81:2231-2239.
153. Jones D.L., Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J. Virol. 1997, 71:2905-2912.
154. Jones D.L., Alani R.M., Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 1997, 11:2101-2111.
155. Jones D.L., Thompson D.A., Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997, 239:97-107.
156. Jones D.L., Thompson D.A., Suh-Burgmann E., Grace M., Munger K. Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway. Virology 1999, 258:406-414.
157. Katzenellenbogen R.A., Vliet-Gregg P., Xu M., Galloway D.A. NFX1-123 increases hTERT expression and telomerase activity posttranscriptionally in human papillomavirus type 16 E6 keratinocytes. J. Virol. 2009, 83:6446-6456.
158. Kaur P., McDougall J.K. Characterization of primary human keratinocytes transformed by human papillomavirus type 18. J. Virol. 1988, 62:1917-1924.
159. Kaur P., McDougall J.K., Cone R. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames. J. Gen. Virol. 1989, 70(Pt 5):1261-1266.
160. Kessis T.D., Slebos R.J., Nelson W.G., Kastan M.B., Plunkett B.S., Han S.M., Lorincz A.T., Hedrick L., Cho K.R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3988-3992.
161. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11612-11616.
162. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998, 396:84-88.
163. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380:79-82.
164. Knapp A.A., McManus P.M., Bockstall K., Moroianu J. Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology 2009, 383:60-68.
165. Korzeniewski N., Treat B., Duensing S. The HPV-16 E7 oncoprotein induces centriole multiplication through deregulation of Polo-like kinase 4 expression. Mol. Cancer 2011, 10:61.
166. Krawczyk E., Suprynowicz F.A., Liu X., Dai Y., Hartmann D.P., Hanover J., Schlegel R. Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am. J. Pathol. 2008, 173:682-688.
167. Kuhne C., Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J. Biol. Chem. 1998, 273:34302-34309.
168. Kukimoto I., Aihara S., Yoshiike K., Kanda T. Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein. Biochem. Biophys. Res. Commun. 1998, 249:258-262.
169. Kumar A., Zhao Y., Meng G., Zeng M., Srinivasan S., Delmolino L.M., Gao Q., Dimri G., Weber G.F., Wazer D.E., Band H., Band V. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol. Cell. Biol. 2002, 22:5801-5812.
170. Lambert P.F., Pan H., Pitot H.C., Liem A., Jackson M., Griep A.E. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5583-5587.
171. Laurson J., Khan S., Chung R., Cross K., Raj K. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 2010, 31:918-926.
172. Lechner M.S., Laimins L.A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 1994, 68:4262-4273.
173. Lee S.S., Glaunsinger B., Mantovani F., Banks L., Javier R.T. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J. Virol. 2000, 74:9680-9693.
174. Leechanachai P., Banks L., Moreau F., Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992, 7:19-25.
175. Li X., Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 1996, 70:4509-4516.
176. Li S., Labrecque S., Gauzzi M.C., Cuddihy A.R., Wong A.H., Pellegrini S., Matlashewski G.J., Koromilas A.E. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18:5727-5737.
177. Lichtig H., Gilboa D.A., Jackman A., Gonen P., Levav-Cohen Y., Haupt Y., Sherman L. HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. Virology 2010, 396:47-58.
178. Lin Z., Yemelyanova A.V., Gambhira R., Jagu S., Meyers C., Kirnbauer R., Ronnett B.M., Gravitt P.E., Roden R.B. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am. J. Pathol. 2009, 174:136-143.
179. Liu Y., Chen J.J., Gao Q., Dalal S., Hong Y., Mansur C.P., Band V., Androphy E.J. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J. Virol. 1999, 73:7297-7307.
180. Liu X., Yuan H., Fu B., Disbrow G.L., Apolinario T., Tomaic V., Kelley M.L., Baker C.C., Huibregtse J., Schlegel R. The E6-AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 2005, 12:10807-10816.
181. Liu X., Clements A., Zhao K., Marmorstein R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 2006, 281:578-586.
182. Liu Y., Heilman S.A., Illanes D., Sluder G., Chen J.J. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy. Cancer Res. 2007, 67:2603-2610.
183. Liu X., Roberts J., Dakic A., Zhang Y., Schlegel R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 2008, 375:611-623.
184. Liu X., Dakic A., Zhang Y., Dai Y., Chen R., Schlegel R. HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18780-18785.
185. Lu Z., Hu X., Li Y., Zheng L., Zhou Y., Jiang H., Ning T., Basang Z., Zhang C., Ke Y. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J. Biol. Chem. 2004, 279:35664-35670.
186. Luscher-Firzlaff J.M., Westendorf J.M., Zwicker J., Burkhardt H., Henriksson M., Muller R., Pirollet F., Luscher B. Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation. Oncogene 1999, 18:5620-5630.
187. Malanchi I., Accardi R., Diehl F., Smet A., Androphy E., Hoheisel J., Tommasino M. Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J. Virol. 2004, 78:13769-13778.
188. Maldonado E., Cabrejos M.E., Banks L., Allende J.E. Human papillomavirus-16 E7 protein inhibits the DNA interaction of the TATA binding transcription factor. J. Cell. Biochem. 2002, 85:663-669.
189. Marcuzzi G.P., Hufbauer M., Kasper H.U., Weissenborn S.J., Smola S., Pfister H. Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J. Gen. Virol. 2009, 90:2855-2864.
190. Massimi P., Banks L. Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. Virology 2000, 276:388-394.
191. Massimi P., Pim D., Storey A., Banks L. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 1996, 12:2325-2330.
192. Massimi P., Pim D., Banks L. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J. Gen. Virol. 1997, 78(Pt 10):2607-2613.
193. Matlashewski G., Schneider J., Banks L., Jones N., Murray A., Crawford L. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J. 1987, 6:1741-1746.
194. Maufort J.P., Williams S.M., Pitot H.C., Lambert P.F. Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res. 2007, 67:6106-6112.
195. Maufort J.P., Shai A., Pitot H.C., Lambert P.F. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res. 2010, 70:2924-2931.
196. McCance D.J., Kopan R., Fuchs E., Laimins L.A. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:7169-7173.
197. McCloskey R., Menges C., Friedman A., Patel D., McCance D.J. Human papillomavirus type 16 E6/E7 upregulation of nucleophosmin is important for proliferation and inhibition of differentiation. J. Virol. 2010, 84:5131-5139.
198. McIntyre M.C., Frattini M.G., Grossman S.R., Laimins L.A. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J. Virol. 1993, 67:3142-3150.
199. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384:335-344.
200. McLaughlin-Drubin M.E., Bromberg-White J.L., Meyers C. The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 2005, 338:61-68.
201. McLaughlin-Drubin M.E., Huh K.W., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J. Virol. 2008, 82:8695-8705.
202. McLaughlin-Drubin M.E., Crum C.P., Munger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2130-2135.
203. Melar-New M., Laimins L.A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J. Virol. 2010, 84:5212-5221.
204. Melillo R.M., Helin K., Lowy D.R., Schiller J.T. Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins. Mol. Cell. Biol. 1994, 14:8241-8249.
205. Menges C.W., Baglia L.A., Lapoint R., McCance D.J. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res. 2006, 66:5555-5559.
206. Mileo A.M., Abbruzzese C., Mattarocci S., Bellacchio E., Pisano P., Federico A., Maresca V., Picardo M., Giorgi A., Maras B., Schinina M.E., Paggi M.G. Human papillomavirus-16 E7 interacts with glutathione S-transferase P1 and enhances its role in cell survival. PLoS One 2009, 4:e7254.
207. Moody C.A., Laimins L.A. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 2009, 5:e1000605.
208. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 2010, 10:550-560.
209. Moody C.A., Fradet-Turcotte A., Archambault J., Laimins L.A. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19541-19546.
210. Morgan D.M., Pecoraro G., Rosenberg I., Defendi V. Transformation by human papillomavirus type 16 (HPV16) DNA but not HPV6b DNA is enhanced by addition of the human cytomegalovirus enhancer. Virology 1992, 189:687-694.
211. Morosov A., Phelps W.C., Raychaudhuri P. Activation of the c-fos gene by the HPV16 oncoproteins depends upon the cAMP-response element at ?60. J. Biol. Chem. 1994, 269:18434-18440.
212. Morozov A., Shiyanov P., Barr E., Leiden J.M., Raychaudhuri P. Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21. J. Virol. 1997, 71:3451-3457.
213. Morris J.D., Crook T., Bandara L.R., Davies R., LaThangue N.B., Vousden K.H. Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene 1993, 8:893-898.
214. Muench P., Hiller T., Probst S., Florea A.M., Stubenrauch F., Iftner T. Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. Virology 2009, 387:380-387.
215. Muench P., Probst S., Schuetz J., Leiprecht N., Busch M., Wesselborg S., Stubenrauch F., Iftner T. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res 2010, 10.1158/0008-5472.CAN-10-1307.
216. Muller C., Alunni-Fabbroni M., Kowenz-Leutz E., Mo X., Tommasino M., Leutz A. Separation of C/EBPalpha-mediated proliferation arrest and differentiation pathways. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7276-7281.
217. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63:4417-4421.
218. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989, 8:4099-4105.
219. Munger K., Yee C.L., Phelps W.C., Pietenpol J.A., Moses H.L., Howley P.M. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 1991, 65:3943-3948.
220. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 2004, 78:11451-11460.
221. Murakami Y., Eki T., Yamada M., Prives C., Hurwitz J. Species-specific in vitro synthesis of DNA containing the polyoma virus origin of replication. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:6347-6351.
222. Nakagawa S., Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 2000, 20:8244-8253.
223. Nakahara T., Lambert P.F. Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus. Virology 2007, 366:316-329.
224. Narahari J., Fisk J.C., Melendy T., Roman A. Interactions of the cellular CCAAT displacement protein and human papillomavirus E2 protein with the viral origin of replication can regulate DNA replication. Virology 2006, 350:302-311.
225. Nees M., Geoghegan J.M., Munson P., Prabhu V., Liu Y., Androphy E., Woodworth C.D. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res. 2000, 60:4289-4298.
226. Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 2001, 75:4283-4296.
227. Nguyen C.L., Munger K. Human papillomavirus E7 protein deregulates mitosis via an association with nuclear mitotic apparatus protein 1. J. Virol. 2009, 83:1700-1707.
228. Nguyen D.X., Westbrook T.F., McCance D.J. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J. Virol. 2002, 76:619-632.
229. Nguyen C.L., Eichwald C., Nibert M.L., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin. J. Virol. 2007, 81:13533-13543.
230. Nomine Y., Masson M., Charbonnier S., Zanier K., Ristriani T., Deryckere F., Sibler A.P., Desplancq D., Atkinson R.A., Weiss E., Orfanoudakis G., Kieffer B., Trave G. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol. Cell 2006, 21:665-678.
231. Nor Rashid N., Yusof R., Watson R.J. Disruption of repressive p130-DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells. J. Gen. Virol. 2011, 92:2620-2627.
232. O'Connor M.J., Stunkel W., Koh C.H., Zimmermann H., Bernard H.U. The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses through a conserved silencing element. J. Virol. 2000, 74:401-410.
233. Oh S.T., Kyo S., Laimins L.A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 2001, 75:5559-5566.
234. Oh S.T., Longworth M.S., Laimins L.A. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J. Virol. 2004, 78:2620-2626.
235. Ohlenschlager O., Seiboth T., Zengerling H., Briese L., Marchanka A., Ramachandran R., Baum M., Korbas M., Meyer-Klaucke W., Durst M., Gorlach M. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 2006, 25:5953-5959.
236. Orth G. Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin. Immunol. 2006, 18:362-374.
237. Park R.B., Androphy E.J. Genetic analysis of high-risk e6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes. J. Virol. 2002, 76:11359-11364.
238. Patel D., Huang S.M., Baglia L.A., McCance D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999, 18:5061-5072.
239. Pater M.M., Hughes G.A., Hyslop D.E., Nakshatri H., Pater A. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature 1988, 335:832-835.
240. Patrick D.R., Oliff A., Heimbrook D.C. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 1994, 269:6842-6850.
241. Pecoraro G., Morgan D., Defendi V. Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:563-567.
242. Pecoraro G., Lee M., Morgan D., Defendi V. Evolution of in vitro transformation and tumorigenesis of HPV16 and HPV18 immortalized primary cervical epithelial cells. Am. J. Pathol. 1991, 138:1-8.
243. Pei X.F., Sherman L., Sun Y.H., Schlegel R. HPV-16 E7 protein bypasses keratinocyte growth inhibition by serum and calcium. Carcinogenesis 1998, 19:1481-1486.
244. Phelps W.C., Yee C.L., Munger K., Howley P.M. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988, 53:539-547.
245. Phelps W.C., Munger K., Yee C.L., Barnes J.A., Howley P.M. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 1992, 66:2418-2427.
246. Phillips A.C., Vousden K.H. Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP. J. Gen. Virol. 1997, 78(Pt 4):905-909.
247. Pietsch E.C., Murphy M.E. Low risk HPV-E6 traps p53 in the cytoplasm and induces p53-dependent apoptosis. Cancer Biol. Ther. 2008, 7:1916-1918.
248. Pim D., Banks L. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 1999, 18:7403-7408.
249. Pim D., Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010, 118:471-493.
250. Pim D., Storey A., Thomas M., Massimi P., Banks L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 1994, 9:1869-1876.
251. Pim D., Massimi P., Banks L. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 1997, 15:257-264.
252. Pim D., Thomas M., Banks L. Chimaeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins. Oncogene 2002, 21:8140-8148.
253. Pim D., Massimi P., Dilworth S.M., Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 2005, 24:7830-7838.
254. Pim D., Tomaic V., Banks L. The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein. J. Virol. 2009, 83:9863-9874.
255. Pirisi L., Yasumoto S., Feller M., Doniger J., DiPaolo J.A. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J. Virol. 1987, 61:1061-1066.
256. Pirisi L., Creek K.E., Doniger J., DiPaolo J.A. Continuous cell lines with altered growth and differentiation properties originate after transfection of human keratinocytes with human papillomavirus type 16 DNA. Carcinogenesis 1988, 9:1573-1579.
257. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem. 2010, 336:25-37.
258. Psyrri A., DeFilippis R.A., Edwards A.P., Yates K.E., Manuelidis L., DiMaio D. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res. 2004, 64:3079-3086.
259. Rawls J.A., Pusztai R., Green M. Chemical synthesis of human papillomavirus type 16 E7 oncoprotein: autonomous protein domains for induction of cellular DNA synthesis and for trans activation. J. Virol. 1990, 64:6121-6129.
260. Regan J.A., Laimins L.A. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 2008, 82:10042-10051.
261. Richard C., Lanner C., Naryzhny S.N., Sherman L., Lee H., Lambert P.F., Zehbe I. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene 2010, 29:3435-3445.
262. Riley R.R., Duensing S., Brake T., Munger K., Lambert P.F., Arbeit J.M. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003, 63:4862-4871.
263. Ronco L.V., Karpova A.Y., Vidal M., Howley P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 1998, 12:2061-2072.
264. Ruesch M.N., Laimins L.A. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J. Virol. 1997, 71:5570-5578.
265. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
266. Sang B.C., Barbosa M.S. Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:8063-8067.
267. Sato H., Furuno A., Yoshiike K. Expression of human papillomavirus type 16 E7 gene induces DNA synthesis of rat 3Y1 cells. Virology 1989, 168:195-199.
268. Schaper I.D., Marcuzzi G.P., Weissenborn S.J., Kasper H.U., Dries V., Smyth N., Fuchs P., Pfister H. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res. 2005, 65:1394-1400.
269. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
270. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
271. Schiller J.T., Day P.M., Kines R.C. Current understanding of the mechanism of HPV infection. Gynecol. Oncol. 2010, 118:S12-S17.
272. Schlegel R., Phelps W.C., Zhang Y.L., Barbosa M. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J. 1988, 7:3181-3187.
273. Schmitt A., Harry J.B., Rapp B., Wettstein F.O., Iftner T. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J. Virol. 1994, 68:7051-7059.
274. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985, 314:111-114.
275. Seavey S.E., Holubar M., Saucedo L.J., Perry M.E. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J. Virol. 1999, 73:7590-7598.
276. Sedman S.A., Barbosa M.S., Vass W.C., Hubbert N.L., Haas J.A., Lowy D.R., Schiller J.T. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J. Virol. 1991, 65:4860-4866.
277. Sekaric P., Cherry J.J., Androphy E.J. Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT. J. Virol. 2008, 82:71-76.
278. Shai A., Brake T., Somoza C., Lambert P.F. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 2007, 67:1626-1635.
279. Sherman L., Schlegel R. Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J. Virol. 1996, 70:3269-3279.
280. Sherman L., Alloul N., Golan I., Durst M., Baram A. Expression and splicing patterns of human papillomavirus type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV 16, and in cell lines established from cervical cancers. Int. J. Cancer 1992, 50:356-364.
281. Sherman L., Jackman A., Itzhaki H., Stoppler M.C., Koval D., Schlegel R. Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation. Virology 1997, 237:296-306.
282. Simonson S.J., Difilippantonio M.J., Lambert P.F. Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res. 2005, 65:8266-8273.
283. Smith-McCune K., Kalman D., Robbins C., Shivakumar S., Yuschenkoff L., Bishop J.M. Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6999-7004.
284. Smotkin D., Wettstein F.O. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 1987, 61:1686-1689.
285. Smotkin D., Prokoph H., Wettstein F.O. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J. Virol. 1989, 63:1441-1447.
286. Song S., Pitot H.C., Lambert P.F. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J. Virol. 1999, 73:5887-5893.
287. Spangle J.M., Munger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J. Virol. 2010, 84:9398-9407.
288. Spanos W.C., Geiger J., Anderson M.E., Harris G.F., Bossler A.D., Smith R.B., Klingelhutz A.J., Lee J.H. Deletion of the PDZ motif of HPV16 E6 preventing immortalization and anchorage-independent growth in human tonsil epithelial cells. Head Neck 2008, 30:139-147.
289. Spanos W.C., Hoover A., Harris G.F., Wu S., Strand G.L., Anderson M.E., Klingelhutz A.J., Hendriks W., Bossler A.D., Lee J.H. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J. Virol. 2008, 82:2493-2500.
290. Spardy N., Covella K., Cha E., Hoskins E.E., Wells S.I., Duensing A., Duensing S. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res. 2009, 69:7022-7029.
291. Sprague D., Phillips S., Mitchell C., Berger K., Lace M., Turek L., Klingelhutz A. Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomes. Virology 2002, 301:247.
292. Srivenugopal K.S., Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene 2002, 21:5940-5945.
293. Stoppler M.C., Straight S.W., Tsao G., Schlegel R., McCance D.J. The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Virology 1996, 223:251-254.
294. Stoppler H., Stoppler M.C., Johnson E., Simbulan-Rosenthal C.M., Smulson M.E., Iyer S., Rosenthal D.S., Schlegel R. The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene 1998, 17:1207-1214.
295. Storey A., Banks L. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene 1993, 8:919-924.
296. Storey A., Pim D., Murray A., Osborn K., Banks L., Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J. 1988, 7:1815-1820.
297. Storey A., Almond N., Osborn K., Crawford L. Mutations of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J. Gen. Virol. 1990, 71(Pt 4):965-970.
298. Storey A., Osborn K., Crawford L. Co-transformation by human papillomavirus types 6 and 11. J. Gen. Virol. 1990, 71(Pt 1):165-171.
299. Straight S.W., Hinkle P.M., Jewers R.J., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 1993, 67:4521-4532.
300. Straight S.W., Herman B., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 1995, 69:3185-3192.
301. Strati K., Lambert P.F. Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res. 2007, 67:11585-11593.
302. Strati K., Pitot H.C., Lambert P.F. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14152-14157.
303. Sun Y., Jiang X., Price B.D. Tip60: connecting chromatin to DNA damage signaling. Cell Cycle 2010, 9:930-936.
304. Suprynowicz F.A., Disbrow G.L., Krawczyk E., Simic V., Lantzky K., Schlegel R. HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 2008, 27:1071-1078.
305. Suprynowicz F.A., Krawczyk E., Hebert J.D., Sudarshan S.R., Simic V., Kamonjoh C.M., Schlegel R. The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. J. Virol. 2010, 84:10619-10629.
306. Takami Y., Sasagawa T., Sudiro T.M., Yutsudo M., Hakura A. Determination of the functional difference between human papillomavirus type 6 and 16 E7 proteins by their 30 N-terminal amino acid residues. Virology 1992, 186:489-495.
307. Tang S., Tao M., McCoy J.P., Zheng Z.M. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 2006, 80:4249-4263.
308. Thomas M., Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 1999, 80:1513-1517.
309. Thomas M.C., Chiang C.M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell 2005, 17:251-264.
310. Thomas J.T., Laimins L.A. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J. Virol. 1998, 72:1131-1137.
311. Thomas M., Massimi P., Jenkins J., Banks L. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 1995, 10:261-268.
312. Thomas J.T., Hubert W.G., Ruesch M.N., Laimins L.A. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8449-8454.
313. Thomas J.T., Oh S.T., Terhune S.S., Laimins L.A. Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J. Virol. 2001, 75:7564-7571.
314. Thomas M., Laura R., Hepner K., Guccione E., Sawyers C., Lasky L., Banks L. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 2002, 21:5088-5096.
315. Thomas M., Narayan N., Pim D., Tomaic V., Massimi P., Nagasaka K., Kranjec C., Gammoh N., Banks L. Human papillomaviruses, cervical cancer and cell polarity. Oncogene 2008, 27:7018-7030.
316. Thomsen P., van Deurs B., Norrild B., Kayser L. The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene 2000, 19:6023-6032.
317. Todorovic B., Massimi P., Hung K., Shaw G.S., Banks L., Mymryk J.S. Systematic analysis of the amino acid residues of human papillomavirus type 16 e7 conserved region 3 involved in dimerization and transformation. J. Virol. 2011, 85:10048-10057.
318. Tommasino M., Adamczewski J.P., Carlotti F., Barth C.F., Manetti R., Contorni M., Cavalieri F., Hunt T., Crawford L. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993, 8:195-202.
319. Tong X., Salgia R., Li J.L., Griffin J.D., Howley P.M. The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J. Biol. Chem. 1997, 272:33373-33376.
320. Tsunokawa Y., Takebe N., Kasamatsu T., Terada M., Sugimura T. Transforming activity of human papillomavirus type 16 DNA sequence in a cervical cancer. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2200-2203.
321. Tungteakkhun S.S., Filippova M., Fodor N., Duerksen-Hughes P.J. The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J. Virol. 2010, 84:1453-1463.
322. Underbrink M.P., Howie H.L., Bedard K.M., Koop J.I., Galloway D.A. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J. Virol. 2008, 82:10408-10417.
323. Uversky V.N., Roman A., Oldfield C.J., Dunker A.K. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs. J. Proteome Res. 2006, 5:1829-1842.
324. Valle G.F., Banks L. The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J. Gen. Virol. 1995, 76(Pt 5):1239-1245.
325. Veldman T., Horikawa I., Barrett J.C., Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol. 2001, 75:4467-4472.
326. Veldman T., Liu X., Yuan H., Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8211-8216.
327. Vousden K.H., Jat P.S. Functional similarity between HPV16E7, SV40 large T and adenovirus E1a proteins. Oncogene 1989, 4:153-158.
328. Vousden K.H., Doniger J., DiPaolo J.A., Lowy D.R. The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res. 1988, 3:167-175.
329. Vousden K.H., Vojtesek B., Fisher C., Lane D. HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 1993, 8:1697-1702.
330. Wang Y., Okan I., Pokrovskaja K., Wiman K.G. Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis. Oncogene 1996, 12:2731-2735.
331. Wang H.K., Duffy A.A., Broker T.R., Chow L.T. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 2009, 23:181-194.
332. Wang X., Wang H.K., McCoy J.P., Banerjee N.S., Rader J.S., Broker T.R., Meyers C., Chow L.T., Zheng Z.M. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009, 15:637-647.
333. Watanabe S., Kanda T., Sato H., Furuno A., Yoshiike K. Mutational analysis of human papillomavirus type 16 E7 functions. J. Virol. 1990, 64:207-214.
334. Watanabe S., Sato H., Komiyama N., Kanda T., Yoshiike K. The E7 functions of human papillomaviruses in rat 3Y1 cells. Virology 1992, 187:107-114.
335. Watkins J.F., Dulbecco R. Production of SV40 virus in heterokaryons of transformed and susceptible cells. Proc. Natl. Acad. Sci. U. S. A. 1967, 58:1396-1403.
336. Watson R.A., Thomas M., Banks L., Roberts S. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J. Cell Sci. 2003, 116:4925-4934.
337. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79.
338. Westbrook T.F., Nguyen D.X., Thrash B.R., McCance D.J. E7 abolishes raf-induced arrest via mislocalization of p21(Cip1). Mol. Cell. Biol. 2002, 22:7041-7052.
339. Westphal K., Akgul B., Storey A., Nindl I. Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures. Cell. Oncol. 2009, 31:213-226.
340. Wise-Draper T.M., Wells S.I. Papillomavirus E6 and E7 proteins and their cellular targets. Front. Biosci. 2008, 13:1003-1017.
341. Wise-Draper T.M., Allen H.V., Thobe M.N., Jones E.E., Habash K.B., Munger K., Wells S.I. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J. Virol. 2005, 79:14309-14317.
342. Wong H.K., Ziff E.B. The human papillomavirus type 16 E7 protein complements adenovirus type 5 E1A amino-terminus-dependent transactivation of adenovirus type 5 early genes and increases ATF and Oct-1 DNA binding activity. J. Virol. 1996, 70:332-340.
343. Woodworth C.D., Bowden P.E., Doniger J., Pirisi L., Barnes W., Lancaster W.D., DiPaolo J.A. Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA. Cancer Res. 1988, 48:4620-4628.
344. Woodworth C.D., Doniger J., DiPaolo J.A. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J. Virol. 1989, 63:159-164.
345. Wu E.W., Clemens K.E., Heck D.V., Munger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol. 1993, 67:2402-2407.
346. Xu M., Luo W., Elzi D.J., Grandori C., Galloway D.A. NFX1 interacts with mSin3A/HDAC to repress hTERT transcription in keratinocytes. Mol. Cell. Biol. 2008, 28:4819-4828.
347. Xu M., Katzenellenbogen R.A., Grandori C., Galloway D.A. NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity. J. Virol. 2010, 84:11461-11469.
348. Yamashita T., Segawa K., Fujinaga Y., Nishikawa T., Fujinaga K. Biological and biochemical activity of E7 genes of the cutaneous human papillomavirus type 5 and 8. Oncogene 1993, 8:2433-2441.
349. Yasumoto S., Burkhardt A.L., Doniger J., DiPaolo J.A. Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J. Virol. 1986, 57:572-577.
350. Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 1985, 119:361-366.
351. Yuan H., Fu F., Zhuo J., Wang W., Nishitani J., An D.S., Chen I.S., Liu X. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene 2005, 24:5069-5078.
352. Yugawa T., Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev. Med. Virol. 2009, 19:97-113.
353. Zerfass-Thome K., Zwerschke W., Mannhardt B., Tindle R., Botz J.W., Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996, 13:2323-2330.
354. Zhang B., Laribee R.N., Klemsz M.J., Roman A. Human papillomavirus type 16 E7 protein increases acetylation of histone H3 in human foreskin keratinocytes. Virology 2004, 329:189-198.
355. Zhang B., Srirangam A., Potter D.A., Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005, 24:2585-2588.
356. Zhang Y., Fan S., Meng Q., Ma Y., Katiyar P., Schlegel R., Rosen E.M. BRCA1 interaction with human papillomavirus oncoproteins. J. Biol. Chem. 2005, 280:33165-33177.
357. Zhang B., Chen W., Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:437-442.
358. Zheng Z.M., Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim. Biophys. Acta. 2011, 1809:668-677.
359. Zheng Z.M., Tao M., Yamanegi K., Bodaghi S., Xiao W. Splicing of a cap-proximal human papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by distance of the intron from its RNA 5? cap. J. Mol. Biol. 2004, 337:1091-1108.
360. Zheng L., Ding H., Lu Z., Li Y., Pan Y., Ning T., Ke Y. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. Genes Cells 2008, 13:285-294.
361. Zhou X., Munger K. Expression of the human papillomavirus type 16 E7 oncoprotein induces an autophagy-related process and sensitizes normal human keratinocytes to cell death in response to growth factor deprivation. Virology 2009, 385:192-197.
362. Zhou X., Spangle J.M., Munger K. Expression of a viral oncoprotein in normal human epithelial cells triggers an autophagy-related process: is autophagy an "Achilles' heel" of human cancers?. Autophagy 2009, 5:578-579.
363. Zimmermann H., Degenkolbe R., Bernard H.U., O'Connor M.J. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 1999, 73:6209-6219.
364. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009, 384:260-265.
365. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.
366. Zwerschke W., Mazurek S., Massimi P., Banks L., Eigenbrodt E., Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1291-1296.